OVER the past decade, much has been learned regarding the role of various cytokines in the pathogenesis of in ammatory bowel disease. Several cytokine 'knockout' models in mice have been shown to develop colitis, while alterations in the production of various cytokines has been documented in human Crohn's disease and ulcerative colitis. In recent years, attempts have been made to treat these diseases through modulation of cytokine production or action. This review focuses on the cytokines that have been implicated in the pathogenesis of in ammatory bowel disease. The evidence for and against a role for particular cytokines in intestinal in ammation is reviewed, as is the ex perimental and clinical data suggesting that cytokines are rational targets for the development of new therapies.
Introduction
'In ammatory bowel disease' (IBD) is an umbrella term used to describe at least two distinct diseases: ulcerative colitis (UC) and Crohn's disease (CD). UC and CD are chronic in ammatory conditions affecting the gastrointestinal tract and are typi ed by unpredictable periods of remission and relapse. UC affects the large intestine and is usually limited to the mucosal layer. CD is a transmural disease (extending to the depth of the muscularis externae) and can occur anywhere in the gastrointestinal tract, although it most frequently affects the terminal ileum and large intestine.
Current treatment of IBD, which is modestly effective at best, primarily involves the use of corticosteroids, 5-amino salicylic acid, and to a lesser extent, immunosuppressants and antimicrobials. The pathogenesis of IBD remains poorly understood, hampering efforts to develop more effective treatments. It is generally believed that an impaired mucosal immune response to luminal microbes leads to an unrelenting in ammatory response with the generation of non-speci c 'bystander' injury to the intestinal tissue. Considerable research in recent years has been directed at further understanding the mechanisms involved in regulating the in ammatory response in IBD. Several mediators are thought to play a role in this response and/or to contribute to the tissue injury and generation of symptoms, including nitric oxide, histamine, eicosanoids and cytokines. Given the key role of several cytokines in regulating mucosal immune responses, this family of mediators has received special attention by IBD researchers in the past decade. This review focuses on the emerging evidence for a role for various cytokines in the pathogenesis of IBD, and the possibility that these mediators represent rationale targets for therapeutic intervention. These cytokines can be divided into two categories: those that upregulate and those that downregulate the in ammatory response.
Pro-in¯ammatory Cytokines
Interleukin-1 (IL-1) IL-1 is released early in the in ammatory cascade and has numerous pro-in ammatory actions (Table 1) . IL-1 is produced by a wide array of cells, including macrophages, monocytes, endothelial cells and broblasts. 1 Two receptors for IL-1 have been identi ed. Type I receptors are found primarily on T lymphocytes and broblasts, while type II receptors have been identi ed on B lymphocytes, macrophages and monocytes.
1 IL-1 receptor antagonist (IL-1ra) is a naturally occurring antagonist to both IL-1 receptors that is produced by many of the same cells that produce IL-1. IL-1 activity is, therefore, determined by the balance between its levels and those of IL-1ra at any target cell or tissue. 1 Elevated levels of IL-1 activity in plasma and tissue have been demonstrated in both CD and UC, as well as in several experimental models of colitis. 2 9 Furthermore, the ratio of IL-1:IL-1ra is increased in CD and UC but not in self-limited colitis 8 ( Fig. 1) . The pivotal role of IL-1 and IL1ra in regulating colonic in ammation has been demonstrated by the observation that administration of recombinant IL-1ra attenuates the in ammatory process in three different animal models of colitis. 10 12 The importance of IL-1ra was further demonstrated in a rabbit model of immune-complex colitis, where in ammation of the colon was exacerbated by the administration of neutralizing antibodies directed against IL-1ra 13 ( Fig. 2) . Sher et al. found that in patients with CD, IL-1 and IL-8 levels were elevated in in amed and normal colonic tissue.
14 Thus, cytokine activation may occur prior to the development of macroscopically visible damage or may simply involve the entire region of the gut when only limited macroscopic disease exists. A similar pattern was also noted in pouchitis (in ammation of a surgically constructed ileal reservoir). Levels of IL-1, IL-6 and IL-8 were increased in pouchitis, but levels of IL-1 and IL-8 were also increased in non-in amed pouches relative to normal ileal mucosa. The ratio is signi® cantly ( P , 0 01) depressed in patients with UC and CD relative to the other two groups. Prepared using the data Casini-Raggi et al. 8 with permission of the authors.
Therapy directed at regulating IL-1 activity appears promising. Cominelli and co-workers 16 reported that an inhibitor of IL-1 and TNFa synthesis (CGP 47969A) signi cantly decreased the severity of in ammation in a rabbit model of colitis. Clinical trials of recombinant IL-1ra were initiated a number of years ago, but were not completed due to disappointing results from trials of this cytokine unrelated to IBD. For several years, nicotine has been suggested to decrease activity in UC and recently it has been found to be effective in the treatment of active UC (but not in the maintenance of remission). 17, 18 The mechanism of action of nicotine in the treatment of UC is not well understood, but it has been suggested to be due to its ability to suppress the production of IL-1 and TNFa. 19 
Interleukin-2 (IL-2)
IL-2 is a key factor in the regulation of T lymphocyte proliferation. 1 It also in uences proliferation of B lymphocytes and natural killer (NK) cells. High and low af nity receptors for IL-2 have been identi ed on several cells. 1 3 IL-2 levels and IL-2 responses are increased in CD, but decreased in UC. 20, 21 In peripheral blood monocytes isolated from paediatric patients with IBD, indomethacin increased IL-2 production in monocytes from CD patients but not in those from UC patients. 22 A potential role of IL-2 in the pathogenesis of IBD was suggested when two patients with CD received high-dose IL-2 for the treatment of renal cell carcinoma 23 and both experienced a are in CD symptoms requiring immediate bowel resection. 23 In terms of IL-2-related therapy, cyclosporin A, FK506, and rapamycin are all inhibitors of lymphocyte activation and decrease IL-2 synthesis and/or IL-2 responsiveness. Cyclosporin A has been shown to exhibit some ef cacy in the treatment of IBD, 24, 25 while FK506 has shown promise in an animal model of colitis. 26 
Interleukin-5 (IL-5)
IL-5 is among the most potent chemotaxins for eosinophils yet described, and can enhance immunoglobulin A secretion by B lymphocytes. 1 3 In a study looking at early recurrence of CD following resection, Dubucquoi et al. found that eosinophil in ltration was more pronounced in areas with endoscopically visible disease compared with normal-appearing tissue, and that increased numbers of eosinophils were associated with elevated IL-5 mRNA expression. 27 However, more direct evidence for a role of IL-5 in IBD is lacking.
Only one study has examined the role of IL-5 in experimental colitis, yielding results that were inconclusive. The severity of dextran sulphate sodium-induced colitis in mice in which the gene for IL-5 had been deleted (IL-5 knock-out mice) was found not to differ from that in normal mice. 28 Given the high likelihood that there is redundancy in terms of the number of mediators that can produce the pro-in ammatory effects ascribed to IL-5, and that there may be up-regulation of the production of these other mediators as a means of compensating for the lack of IL-5 in the knock-out mice, one cannot draw any rm conclusions from this study regarding the role of IL-5 in colitis.
Interleukin-6 (IL-6)
IL-6 appears to be one of the most important cytokines in the in ammatory response. The main actions of IL-6 include activation of T and B lymphocytes and induction of hepatic acute phase reactants. 29 Previous studies noted elevations of IL-6 in both CD and UC and more recently in pouchitis. 3, 14, 15, 30 Serum levels of IL-6 and soluble IL-6 receptor as well as tissue levels of IL-6 appear to correlate well with disease activity in both CD and UC. 31, 32 Recently, a group from Belgium found that serum IL-6 levels in patients with inactive CD, followed for one year, correctly predicted whether a patient would relapse in 29 of 32 cases. 33 
Interleukin-8 (IL-8)
IL-8 is a potent chemotaxin for neutrophils. 1 3 Increased IL-8 levels have been demonstrated in Treatment with anti-IL-1ra signi® cantly increased the severity of colitis relative to rabbits treated with a control antibody or to healthy rabbits receiving only saline ( P , 0 03) Prepared using the data of Cominelli et al. 13 with permission of the authors.
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CD, UC and pouchitis tissue, and these levels correlated with disease activity. 15, 34 These studies were recently con rmed by Patel et al. and Sher et al., who also reported elevated levels of IL-8 in non-in amed tissue from ileoanal pouches and CD. 14, 30 The role of IL-1 and TNFa in regulating IL-8 in colitis was demonstrated by Cominelli's group in the study referred to above. 16 They found that an inhibitor of the synthesis of IL-1 and TNFa (CGP 47969A) reduced the severity of damage in a rabbit model of colitis and this reduction of damage was associated with decreased colonic IL-1 and IL-8 levels. 16 IL-8 production by isolated colonic crypt cells is increased in IBD. 35 The short chain fatty acid butyrate was shown to signi cantly reduce IL-8 secretion from these cells, possibly explaining the ef cacy of short chain fatty acids in the treatment of distal UC and diversion colitis. 35 Tumour necrosis factor-a (TNFa)
Like IL-1, TNFa is released from macrophages early in the in ammatory response. TNFa has numerous roles in the in ammatory cascade and has been implicated in the pathogenesis of IBD (Table 1) . Numerous studies have documented marked elevations TNFa in CD, UC and pouchitis. 3,8,14,30,36 38 Tissue, serum and intraluminal concentrations of TNFa have been shown to correlate with disease activity in both UC and CD. 3, 36, 37 Soluble TNFa receptors (sTNF-R), p55 and p75, have previously been shown to be elevated in the serum of patients with CD. 39 More recently, p55 and p75 were noted to be elevated in the urine of patients with either CD or UC, and these levels closely correlated with disease activity. 40 Thus, it is possible that intraluminal, serum or urine levels of TNFa or sTNF-R may aid in assessing and managing the IBD patient.
Recently, therapy aimed at regulation of TNFa activity has been evaluated. A single administration of an anti-TNFa monoclonal antibody (cA2) was found to be ef cacious in 10 patients with CD who were resistant to conventional therapy. 41 In this open label, uncontrolled study, the mean disease severity (CD activity index) had decreased by 55%at 2 weeks and by 73%at 8 weeks following therapy. Endoscopy at 4 weeks' post-cA2 infusion showed near-complete healing of all ulceration. The average duration of response following a single dose of cA2 was 4 months. The extraintestinal manifestations of IBD (two with arthritis and one with pyoderma gangrenosum) also improved dramatically following cA2 administration. A marked reduction of IL-6 and C-reactive protein levels was observed, with the levels remaining below baseline values for up to 6 weeks following cA2 administration. 41 In a smaller study ( ve patients), clinical improvement of CD following treatment with cA2 appeared to correlate with a reduction in levels of cytokines associated with Th1 lymphocytes. 42 A different form of anti-TNFa antibody (CDP571) was also recently evaluated. Two weeks following a single administration of CDP571, the mean CD activity index had decreased from 263 to 167, with six of the 15 patients achieving 'remission' (de ned as a CD activity index of less than 150). 43 A multicentre trial of cA2 is presently underway. In preliminary studies, a single dose of 1 to 20 mg/kg induced a signi cant clinical response in 18 of 20 patients. The dose given did not affect the likelihood of response, but the duration of the response appeared to be dosedependent. 44 A role for cA2 in the treatment of UC remains equivocal at this stage. There has been one report of this antibody being effective in steroid-refractory UC, 45 while in another study cA2 was found to have no effect on reducing the severity of colonic in ammation in UC. 46 The main criticisms of the studies performed to date using anti-TNFa antibodies are the small sample size and, from a mechanistic point of view, how a single infusion of cA2 can have such long-lasting effects. There are some indications that anti-TNFa antibodies may cause a reduction in speci c lymphocyte subsets and thus may act by destroying these cells rather than blocking TNFa. Interestingly, similar results have been noted with the use of cA2 in the treatment of rheumatoid arthritis. 47 
Interferons (IFN)
Interferons a, b and c are part of a family of secreted proteins with potent antiproliferative and immunomodulatory activities. 1 3 Mononuclear cells isolated from the lamina propria of CD patients have been shown to have increased levels of both IFNc and IFNa mRNA. 48 Since there have been reports of both improvement and exacerbation of IBD in patients undergoing IFNa therapy for other illnesses, two studies addressed the use of IFNa in CD. Davidsen et al. reported that only two of ve CD patients treated with IFNa had signi cant reductions in the severity of their disease and all had in uenza-like symptoms related to therapy. 49 Gasche et al. found that in a group of 12 patients with CD that received IFNa and pred-nisolone for 12 weeks followed by IFNa alone for another 12 weeks, none achieved remission and 66% of patients had be withdrawn from trial prematurely. 50 IFNa therapy was associated with signi cant side effects, failed to show any bene cial effect on serum IL-6 and acute phase protein levels and did not decrease the endoscopic severity of the disease. 50 Thus, based on the results from these two small studies, there does not appear to be any therapeutic role for IFNa in the treatment of CD.
Anti-in¯ammatory Cytokines
The main anti-in ammatory cytokines include IL-1ra, IL-4, IL-10, IL-11, IL-13 and TGF-b (Table  2) . IL-1ra has been discussed above.
Interleukin-4 (IL-4)
IL-4 is primarily produced by mast cells and T lymphocytes. This cytokine has numerous actions as noted in Table 2 , including the ability to down-regulate IFNc, IL-1 and TNFa production and stimulate IL-1ra and IL-10 synthesis.
1,2,51
Recently it has been suggested that there is a defect in the ability of IL-4 to regulate the in ammatory response in IBD. Schreiber et al. noted that approximately 100-fold higher levels of IL-4 were required to inhibit monocyte production of IL-1b, TNFa and superoxide anion in patients with CD or UC compared with controls. IL-4 production by T-cells and the expression of IL-4 receptors by monocytes were reduced in patients with UC or CD. This could lead to impaired IL-4 responsiveness in these patients. 51, 52 Interleukin-10 (IL-10)
In humans IL-10 is mainly produced by Th2 cells but it can also be produced by both Th1 cells and monocytes. 53 56 IL-10 has numerous actions but its main role appears to involve inhibition of macrophage and T cell function (Table 2) . 53, 56 There have been con icting reports on IL-10 levels in IBD. In some studies IL-10 was found to be elevated in UC but not CD, suggesting UC had a Th2 pattern (increased IL-4, IL-5, IL-6 and IL-10) of cytokine activation whereas CD displayed a Th1 pattern (increased IL-2 and IFNc). 1,2,53 Kucharzik et al. noted that IL-10 was elevated in the serum of patients with either UC or CD, and the levels of IL-10 correlated well with disease activity. 53 There was no difference in the serum levels of IL-10 from those with active UC compared with those with active CD. 53 The only difference noted was that IL-10 levels correlated well with serum IL-6 and soluble IL-2 receptor levels in those with CD but not in UC patients. 53 The theory that IL-10 regulation is signi cantly different in CD versus UC was further disputed by the ndings of Schreiber et al. 55 They found no difference in the tissue concentrations of IL-10 in patients with CD versus those with UC. 55 It was also noted that the IL-10 downregulation of TNFa and IL-1b secretion by peripheral monocytes was similar in patients with IBD and normal controls. 55 As noted above, patients with IBD have an abnormal IL-1:IL-1ra ratio in favour of increased IL-1 activity. In the study by Schreiber's group, the addition of IL-10 to either peripheral monocytes or intestinal macrophages from patients with IBD could restore the IL-1:IL1ra ratio to that found in cell suspensions from normal controls. 55 Thus, it was hypothesized that IL-10 regulation was intact in IBD and that there was not a true de ciency of IL-10, but there may be a de ciency of IL-10 relative to the degree of in ammation in IBD. Schreiber et al. treated three patients with active UC with IL-10 enemas and all exhibited marked reductions in TNFa and IL-1b secretion, but only a minimal reduction in stool frequency and endoscopic scores. 55 A multicentre trial of the use of IL-10 in CD is presently underway.
There is emerging evidence from animal models for a key role of IL-10 in the maintenance of intestinal mucosal integrity and mucosal immune function. Mice in which the gene for IL-10 has been deleted exhibit profound enterocolitis, which can be prevented through administration of recombinant IL-10.
54 IL-10 can also reduce the severity of colitis in a number of experimental models, although there appears to be some variation in the responsiveness of each model and of the dose required to achieve a signi cant effect. 57 59 IL-10 has also recently been shown to prevent secretagogue-induced epithelial secretion in the rat small intestine, suggesting that it might be an important factor in limiting the development of diarrhoea. Interleukin-11 (IL-11) IL-11 was originally isolated from bone marrow stromal cell lines and was found to have both haematopoietic and non-haematopoietic regulatory actions.
61,62 IL-11 receptor belongs to the same family of cytokine receptors as that for IL-6. Both IL-6 and IL-11 stimulate T cell-dependent B cell maturation and enhance platelet and myeloid cell differentiation. 61, 62 The mechanisms involved in the anti-in ammatory actions of IL-11 are not well understood. It has been found to decrease to the severity of intestinal damage following irradiation, cytoablative drugs or exposure to Clostridium dif cile toxin A. 63 65 IL-11 has also been found to decrease the severity of in ammation in the TNBS, acetic acid and transgenic HLA-B27 models of colitis. 66 68 The role of IL-11 in the in ammatory response in UC and CD has yet to be determined.
Interleukin-13 (IL-13)
IL-13 is a lymphocyte-derived cytokine that appears to have some immunosuppressive actions that are similar to IL-4 and IL-10. IL-13 downregulates the release of IL-1b, IL-6, IL-8 and TNFa from monocytes, and also induces the expression of vascular cell adhesion molecule (VCAM-1). On the other hand, IL-13 can inhibit IFN-induced upregulation of intercellular adhesion molecule-1 (ICAM-1). 69 73 Nitric oxide (NO) synthesis and inducible nitric oxide synthase (iNOS) are increased in the colonic epithelium of patients with UC. 74 In a recent study using a human colonic epithelial cell line, IL-13 downregulated NO release and iNOS expression but IL-10 had no effect. 75 Both IL-4 and IL-13 have been reported to suppress cyclooxygenase-2 expression in osteoblasts, but this interaction has not been studied in the gut. 70 In peripheral monocytes isolated from IBD patients the ability of IL-13 to inhibit the production of pro-in ammatory cytokines was reduced compared with cells from control patients or from patients with inactive IBD. 76 Interestingly, it appears that IL-10 can act synergistically with IL-4 or IL-13 to downregulate pro-in ammatory cytokine production by peripheral blood monocytes in IBD, suggesting that combined immunosuppressive cytokine therapy may be bene cial. 77 IL-13 is also produced by activated mast cells, but the implications of this to IBD has yet to be studied. 78 
Transforming growth factor-b (TGF-b)
TGF-b is a cytokine with several anti-in ammatory properties, including modulating the function and secretory activity of macrophages and other immunocytes.
1 TGF-b is also a promoter of wound healing. 1 There appears to be a signi cant upregulation of TGF-b release in patients with IBD and following intestinal irradiation (Table 2) .
1, 79 82 TGF-b can downregulate intestinal cell proliferation and promote cellular differentiation. 80 TGF-b can also modulate the production of other cytokines, particularly IL1ra (increased), IL-1, TNFa and IFN-c (decreased), 83 can suppress nitric oxide production by macrophages 84 and can reduce leukocyte rolling on the vascular endothelium by inhibiting expression of E-selectin. 85 Mice in which the gene for TGF-b has been deleted develop colitis, suggesting a key role for this cytokine in the maintenance of mucosal integrity and mucosal immune function. 86 More direct evaluation of the role of TGF-b in human IBD has not yet been performed.
Conclusions
While incompletely understood, the pathogenesis of IBD is generally believed to be related to an improperly regulated mucosal immune response to luminal microbes. As central regulators of immune responses, the cytokine family have been extensively studied in human IBD and experimental models of colitis. The observation that severe in ammation of the small and/or large intestine occurs spontaneously in several mouse models in which the genes for various cytokines have been deleted adds support to the hypothesis that perturbations in the cytokine cascade could contribute to the development of IBD. Clinical studies of IBD have begun to reveal marked alterations in the production of certain cytokines, or in the responsiveness of immunocytes to various cytokines. Ultimately, these studies may help to identify potential targets for the therapy of these diseases. Indeed, the early, very promising results with antibodies directed against TNFa suggest that cytokine-targeted therapy may in the future become a mainstream treatment for IBD, or at the very least, may be useful adjuncts to existing therapies in the management of IBD in certain subsets of patients.
